Cited by 215Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesImmune cells in cancer

The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.

Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment

Open access

Yang, Li, Li, Aitian, Lei, Qingyang, Zhang, Yi·2019·Journal of Hematology & Oncology

DOI 10.1186/s13045-019-0804-8PMC PMC6880373

Open this paper in CoChat — free account Open PDF

Abstract

Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent developments in cancer immunotherapy have had significant clinical impact, only a subset of patients exhibits clinical response. Therefore, understanding the molecular mechanisms of immunotherapy resistance is necessary. The mechanisms of immune escape appear to consist of two distinct tumor characteristics: a decrease in effective immunocyte infiltration and function and the accumulation of immunosuppressive cells in the tumor microenvironment. Several host-derived factors may also contribute to immune escape. Moreover, inter-patient heterogeneity predominantly results from differences in somatic mutations between cancers, which has led to the hypothesis that differential activation of specific tumor-intrinsic pathways may explain the phenomenon of immune exclusion in a subset of cancers. Increasing evidence has also shown that tumor-intrinsic signaling plays a key role in regulating the immunosuppressive tumor microenvironment and tumor immune escape. Therefore, understanding the mechanisms underlying immune avoidance mediated by tumor-intrinsic signaling may help identify new therapeutic targets for expanding the efficacy of cancer immunotherapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s13045-019-0804-8

Cites

126 of 126 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Tumor-intrinsic signaling induces the exclusion and dysfunction of effective immunocytes. Oncogenic drivers of tumors, including β-catenin, STAT3, PI3K/PTEN/AKT/mTOR, p53, NF-κB, and RAS/RAF/MAPK signaling, are activated in the tumor microenvironment. These oncogenic signaling pathways not only downregulate the production of chemokines, which further decrease the recruitment of DCs, macrophages, T cells, and NK cells to tumor sites, but also induce immunosuppression of these immunocytes. In addition, tumor-intrinsic signaling can induce PD-L1 expression in tumor cells, leading to T cell dysfunction in the tumor microenvironmentCC BY · PubMed Central

Fig. 2 Tumor-intrinsic signaling mediates the recruitment and differentiation of immunosuppressive cells. Oncogenic pathways in tumor cells can be activated to promote the production of several chemokines and cytokines, which further enhance the recruitment and polarization of immunosuppressive cells, such as TAMs, MDSCs, Tregs, and TANs, to tumor sites. These immunosuppressive cells within the tumor microenvironment may also contribute to immunoresistance in cancersCC BY · PubMed Central

Fig. 3 Tumor-intrinsic signaling as a therapeutic target for cancers. The activation of tumor-intrinsic signaling regulates and promotes the immunosuppressive tumor microenvironment, which includes exclusion and dysfunction of effective immunocytes and recruitment and differentiation of immunosuppressive cells. Therefore, targeting the tumor-intrinsic signaling is a potential strategy for cancer treatmentCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Innate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
The complexity of NF-κB signaling in inflammation and cancer
Hoesel, B., & Schmid, J. A. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-86 · Cited by 3,277
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Spranger, S., Bao, R., & Gajewski, T. F. (2015) · Nature · doi:10.1038/nature14404 · Cited by 2,830
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P. L., Mackiewicz, A. A., Stroyakovskiy, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,763
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433

Show all 126 references

Sorted by citations

Roles of IFN-γ in tumor progression and regression: A review
Jorgovanovic, D., Song, M., Wang, L., & Zhang, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-00228-x · Cited by 1,234
Self-citation
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01247-x · Cited by 762
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Immunosenescence: a key player in cancer development
Lian, J., Yue, Y., Yu, W., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00986-z · Cited by 510
Self-citation
Exosome-based immunotherapy: a promising approach for cancer treatment
Xu, Z., Zeng, S., Gong, Z., & Yan, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01278-3 · Cited by 482
Role of tumor microenvironment in cancer progression and therapeutic strategy
Wang, Q., Shao, X., Zhang, Y., Zhu, M., Wang, F. X. C., Mu, J., Li, J., Yao, H., & Chen, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5698 · Cited by 499
Self-citation
Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 431
Self-citation
Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity
Duong, E., Fessenden, T. B., Lutz, E., Dinter, T., Yim, L., Blatt, S., Bhutkar, A., Wittrup, K. D., & Spranger, S. (2022) · Immunity · doi:10.1016/j.immuni.2021.10.020 · Cited by 372
Mechanisms driving the immunoregulatory function of cancer cells
van Weverwijk, A., & de Visser, K. E. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 288
Contradictory roles of lipid metabolism in immune response within the tumor microenvironment
Yu, W., Lei, Q., Yang, L., Qin, G., Liu, S., Wang, D., Ping, Y., & Zhang, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01200-4 · Cited by 278
Self-citation
Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy
Mirlekar, B. (2022) · SAGE Open Medicine · doi:10.1177/20503121211069012 · Cited by 276
Gene modification strategies for next-generation CAR T cells against solid cancers
Tian, Y., Li, Y., Shao, Y., & Zhang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00890-6 · Cited by 179
Self-citation
Immunosenescence, Inflammaging, and Frailty: Role of Myeloid Cells in Age-Related Diseases
Bleve, A., Motta, F., Durante, B., Pandolfo, C., Selmi, C., & Sica, A. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08909-7 · Cited by 185
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 152
Metabolic Modulation of the Tumor Microenvironment Leads to Multiple Checkpoint Inhibition and Immune Cell Infiltration
Kolb, D., Kolishetti, N., Surnar, B., Sarkar, S., Guin, S., Shah, A. S., & Dhar, S. (2020) · ACS Nano · doi:10.1021/acsnano.9b10037 · Cited by 137
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Kumar, S., Chatterjee, M., Ghosh, P., Ganguly, K. K., Basu, M., & Ghosh, M. K. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.024 · Cited by 135
The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape
dos Santos, D. Z., de Souza, J. C., Pimenta, T. M., Martins, B. D. S., Ribeiro, R. S., Butzene, S. M. S., Tessarolo, N. G., Junior, P. C. M. L., Silva, I. V., & Rangel, L. B. A. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01178-1 · Cited by 136
Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy
Morelli, T., Fujita, K., Redelman‐Sidi, G., & Elkington, P. T. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217260 · Cited by 116
Engineering lactate-modulating nanomedicines for cancer therapy
Chen, J., Zhu, Y., Wu, C., & Shi, J. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00479h · Cited by 109
Oncogenic BRAFV600E Governs Regulatory T-cell Recruitment during Melanoma Tumorigenesis
Shabaneh, T. B., Molodtsov, A. K., Steinberg, S. M., Zhang, P., Torres, G. M., Mohamed, G. A., Boni, A., Curiel, T. J., Angeles, C. V., & Turk, M. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0365 · Cited by 110
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Lei, Y., Li, X., Huang, Q., Zheng, X., & Liu, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617335 · Cited by 94
Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance
Hossain, S. M., & Eccles, M. R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021601 · Cited by 98
UBR5 promotes tumor immune evasion through enhancing IFN-γ-induced PDL1 transcription in triple negative breast cancer
Wu, B., Song, M. L., Dong, Q., Xiang, G., Li, J., Ma, X., & Wei, F. (2022) · Theranostics · doi:10.7150/thno.74989 · Cited by 87
CAR-T Cell Therapy—An Overview of Targets in Gastric Cancer
Bębnowska, D., Grywalska, E., Niedźwiedzka‐Rystwej, P., Sosnowska‐Pasiarska, B., Smok-Kalwat, J., Pasiarski, M., Góźdź, S. S., Roliński, J., & Polkowski, W. P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061894 · Cited by 86
KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer
Liang, W., Liu, H., Zeng, Z., Liang, Z., Xie, H., Li, W., Xiong, L., Liu, Z., Chen, M., Jie, H., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0814 · Cited by 82
mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model
Sittplangkoon, C., Alameh, M.-G., Weissman, D., Lin, P. J. C., Tam, Y. K., Prompetchara, E., & Palaga, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983000 · Cited by 79
“In the tumor microenvironment, immunosuppression and tumor evasion strategies cause an inability of the immune cells to detect and eliminate with subsequent exhaustion (47).”
Background
Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer
Chen, X., Feng, L., Huang, Y., Wu, Y., & Xie, N. (2022) · Cancers · doi:10.3390/cancers15010104 · Cited by 84
Interrelation between Programmed Cell Death and Immunogenic Cell Death: Take Antitumor Nanodrug as an Example
Meng, Q., Ding, B., Ma, P., & Lin, J. (2023) · Small Methods · doi:10.1002/smtd.202201406 · Cited by 75
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Czajka‐Francuz, P., Prendes, M. J., Mankan, A. K., Quintana, Á., Pabla, S., Ramkissoon, S. H., Jensen, T. J., Peiró, S., Severson, E. A., Achyut, B. R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1200646 · Cited by 73
Metabolic reprogramming in the immunosuppression of tumor-associated macrophages
Wang, Y., Wang, D., Yang, L., & Zhang, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002426 · Cited by 71
Self-citation
Implantable and Injectable Biomaterial Scaffolds for Cancer Immunotherapy
Li, J., Luo, Y., Li, B., Xia, Y., Wang, H., & Fu, C. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.612950 · Cited by 64
Effect of neoadjuvant chemotherapy on the immune microenvironment in gastric cancer as determined by multiplex immunofluorescence and T cell receptor repertoire analysis
Xing, X., Shi, J., Jia, Y., Dou, Y., Li, Z., Dong, B., Guo, T., Cheng, X., Li, X., Du, H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003984 · Cited by 63
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response
Sahu, A., Köse, K., Kraehenbuehl, L., Byers, C., Holland, A., Tembo, T., Santella, A., Alfonso, A., Li, M., Cordova, M. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32738-7 · Cited by 65
IL‐33/ST2 as a potential target for tumor immunotherapy
Jiang, W., Lian, J., Yue, Y., & Zhang, Y. (2021) · European Journal of Immunology · doi:10.1002/eji.202149175 · Cited by 59
Self-citation
Research progress on the immune microenvironment and immunotherapy in gastric cancer
Mou, P., Ge, Q., Sheng, R., Zhu, T.-F., Liu, Y., & Ding, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291117 · Cited by 58
Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC
Zhou, K., Huang, S., Hu, L.-P., Zhang, X., Qin, W., Zhang, Y., Yao, L.-L., Yu, Y., Zhou, Y.-Q., Zhu, L., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/6694392 · Cited by 55
Self-citation
Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
Moon, Y., Jeon, S. I., Shim, M. K., & Kim, K. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020411 · Cited by 58
Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv
Yü, P., Li, F., Nan, S., Zhang, D., Shi, X., Shan, J., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00803 · Cited by 51
Self-citation
The functions and regulation of Otubains in protein homeostasis and diseases
Zhu, Q., Fu, Y., Li, L., Liu, C. H., & Zhang, L. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101303 · Cited by 46
Targeting metabolic reprogramming in chronic lymphocytic leukemia
Nie, Y., Yun, X., Zhang, Y., & Wang, X. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00292-z · Cited by 45
Self-citation
The tumor immune microenvironment: implications for cancer immunotherapy, treatment strategies, and monitoring approaches
Racacho, K. J., Shiau, Y., Villa, R., Mahri, S., Tang, M., Lin, T., & Li, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1621812 · Cited by 55
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
Olbryt, M., Rajczykowski, M., & Widłak, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114071 · Cited by 42
Nanoparticle-Based Therapies for Turning Cold Tumors Hot: How to Treat an Immunosuppressive Tumor Microenvironment
Giustarini, G., Pavesi, A., & Adriani, G. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.689245 · Cited by 42
FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression
Hu, Y., Lu, Y. C., Xing, F., & Hsu, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215867 · Cited by 40
Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer
Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário‐Ferreira, N., & Moreira, I. S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100811 · Cited by 38
Tumor-intrinsic IRE1α signaling controls protective immunity in lung cancer
Crowley, M. J. P., Bhinder, B., Markowitz, G. J., Martin, M. T., Verma, A., Sandoval, T. A., Chae, C.-S., Yomtoubian, S., Hu, Y., Chopra, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35584-9 · Cited by 40
Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies
Vu, S. H., Vetrivel, P., Kim, J., & Lee, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810906 · Cited by 37
Impact of immunosenescence and inflammaging on the effects of immune checkpoint inhibitors
Hou, C., Wang, Z., & Lu, X. (2023) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2023.08.001 · Cited by 41
Self‐Carrier Nanoparticles for Delivery of Paclitaxel and IDO Inhibitor to Boost Antitumor Chemo‐Immunotherapy
Li, Z., Pei, Q., Zhao, M., Xie, Z., & Zheng, M. J. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202312500 · Cited by 36
Regulation of aromatase in cancer
Molehin, D., Rasha, F. A., Rahman, R. L., & Pruitt, K. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04099-0 · Cited by 36
Immunosenescence and cancer: Opportunities and challenges
Fu, Z., Xu, H., Yue, L., Zheng, W., Pan, L., Gao, F., & Liu, X. (2023) · Medicine · doi:10.1097/md.0000000000036045 · Cited by 37
Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma
Lin, W., Qiu, X., Sun, P., Ye, Y., Huang, Q., Kong, L., & Lu, J. J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.04.010 · Cited by 38
A2AR-mediated CXCL5 upregulation on macrophages promotes NSCLC progression via NETosis
Lei, Q., Zhen, S., Zhang, L., Zhao, Q., Li, Y., & Zhang, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03689-3 · Cited by 30
Self-citation
Decoding Strategies to Evade Immunoregulators Galectin-1, -3, and -9 and Their Ligands as Novel Therapeutics in Cancer Immunotherapy
Lau, L. S., Mohammed, N. B. B., & Dimitroff, C. J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415554 · Cited by 29
A nanoformulation for immunosuppression reversal and broad-spectrum self-amplifying antitumor ferroptosis-immunotherapy
Yang, Q., Liu, T., Zheng, H., Zhou, Z., Huang, Y., Jia, H., Fu, S., Zhang, X., Zhang, H., Liu, Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121936 · Cited by 29
MicroRNAs as Emerging Regulators of Signaling in the Tumor Microenvironment
Syed, S. N., & Brüne, B. (2020) · Cancers · doi:10.3390/cancers12040911 · Cited by 28
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
Kortekaas, K. E., Santegoets, S. J. A. M., Tas, L., Ehsan, I., Charoentong, P., van Doorn, H. C., van Poelgeest, M. I. E., Mustafa, D. A. M., & van der Burg, S. H. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003671 · Cited by 28
TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Lin, A., Zhang, H., Meng, H., Deng, Z., Gu, T., Luo, P., & Zhang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.667875 · Cited by 27
MTAP deficiency contributes to immune landscape remodelling and tumour evasion
Chang, W., Hsu, S., Zhang, J., Li, J., Yang, D. C. H., Chu, C., Yoo, E. H., Zhang, W., Yu, S., & Chen, C. (2022) · Immunology · doi:10.1111/imm.13587 · Cited by 32
Decreased m6A Modification of CD34/CD276(B7-H3) Leads to Immune Escape in Colon Cancer
Zhou, Y., Zhou, H., Shi, J., Guan, A., Zhu, Y., Hou, Z., & Li, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.715674 · Cited by 26
Hybrid Cell Membrane‐Based Nanoplatforms for Enhanced Immunotherapy against Cancer and Infectious Diseases
Peng, X., Li, Y., Yuan, P., & Ding, X. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304477 · Cited by 27
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD‐1 blockade
Wispelaere, W. D., Annibali, D., Tuyaerts, S., Messiaen, J., Antoranz, A., Shankar, G., Dubroja, N., Herreros‐Pomares, A., Baiden-Amissah, R. E. M., Orban, M., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1655 · Cited by 25
L1CAM Overexpression Promotes Tumor Progression Through Recruitment of Regulatory T Cells in Esophageal Carcinoma
Zhao, X., Liu, S., Chen, X., Zhao, J., Li, F., Zhao, Q., Xie, T., Huang, L., Zhang, Z., Qi, Y., et al. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0182 · Cited by 25
Self-citation
Cellular Immunotherapy in Gastric Cancer: Adoptive Cell Therapy and Dendritic Cell-Based Vaccination
Faghfuri, E., Shadbad, M. A., Faghfouri, A. H., & Soozangar, N. (2022) · Immunotherapy · doi:10.2217/imt-2021-0285 · Cited by 25
Targeting immunosenescence for improved tumor immunotherapy
Liu, Z., Zuo, L., Zhou, Z., Liu, S., Ba, Y., Zuo, A., Ren, Y., Zhang, C., Chen, Y., Ma, H., et al. (2024) · MedComm · doi:10.1002/mco2.777 · Cited by 24
Self-citation
Single‐cell RNA sequencing reveals localized tumour ablation and intratumoural immunostimulant delivery potentiate T cell mediated tumour killing
Hoover, A. R., Liu, K., DeVette, C. I., Krawic, J. R., Medcalf, A. D., West, C. L., Hode, T., Lam, S. S. K., Welm, A. L., Sun, X., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.937 · Cited by 21
Comprehensive Analysis of the Tumor Microenvironment in Cutaneous Melanoma associated with Immune Infiltration
Wang, P., Zhang, X., Sun, N., Zhao, Z., & He, J. (2020) · Journal of Cancer · doi:10.7150/jca.44413 · Cited by 24
Bojungikki-Tang Improves Response to PD-L1 Immunotherapy by Regulating the Tumor Microenvironment in MC38 Tumor-Bearing Mice
Chun, J., Park, S., Yi, J.-M., Ha, I. J., Kang, H. N., & Jeong, M.-K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.901563 · Cited by 23
Proteomics and liquid biopsy characterization of human EMT-related metastasis in colorectal cancer
Huang, M., Fu, L., Yan, H., Cheng, L.-Y., Ru, H., Mo, S., Wei, C., Li, D.-M., Mo, X., Tang, W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.790096 · Cited by 23
The role of tumor necrosis factor receptor superfamily in cancer: insights into oncogenesis, progression, and therapeutic strategies
Xu, J. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00990-x · Cited by 28
Intravenous delivery of STING agonists using acid-sensitive polycationic polymer-modified lipid nanoparticles for enhanced tumor immunotherapy
He, Y., Zheng, K., Qin, X., Wang, S., Li, X., Liu, H., Liu, M., Xu, R., Peng, S., & Pang, Z. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.06.004 · Cited by 20
Immune Modulation and Immunotherapy in Solid Tumors: Mechanisms of Resistance and Potential Therapeutic Strategies
Giri, S., Lamichhane, G., Pandey, J., Khadayat, R., Sindhu, K. C., Devkota, H. P., & Khadka, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072923 · Cited by 22
Monitoring Extracellular Ion and Metabolite Dynamics with Recombinant Nanobody-Fused Biosensors
Burgstaller, S., Wagner, T. R., Bischof, H., Bueckle, S., Padamsey, A., Frecot, D. I., Kaiser, P. D., Skrabak, D., Malli, R., Łukowski, R., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104907 · Cited by 21
Precise delivery of doxorubicin and imiquimod through pH-responsive tumor microenvironment-active targeting micelles for chemo- and immunotherapy
Wen, Y.-H., Hsieh, P.-I., Chiu, H., Chiang, C.-W., Lo, C.-L., & Chiang, Y. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100482 · Cited by 20
Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints
Dulal, D., Boring, A. R., Terrero, D., Johnson, T. L., Tiwari, A. K., & Raman, D. (2023) · Cancers · doi:10.3390/cancers15102774 · Cited by 20
Adoptive CD8 + T-cell grafted with liposomal immunotherapy drugs to counteract the immune suppressive tumor microenvironment and enhance therapy for melanoma
Liu, S., Liu, H., Song, X., Jiang, A., Deng, Y., Yang, C., Sun, D., Jiang, K., Yang, F., & Zheng, Y. (2021) · Nanoscale · doi:10.1039/d1nr04036g · Cited by 18
Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy
Shim, M. K., Song, S. K., Jeon, S. I., Hwang, K. Y., & Kim, K. (2022) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2022.2081683 · Cited by 18
The DARC Side of Inflamm-Aging: Duffy Antigen Receptor for Chemokines (DARC/ACKR1) as a Potential Biomarker of Aging, Immunosenescence, and Breast Oncogenesis among High-Risk Subpopulations
Jinna, N., Rida, P. C. G., Su, T., Gong, Z., Yao, S., LaBarge, M. A., Natarajan, R. D., Jovanović‐Talisman, T., Ambrosone, C. B., & Seewaldt, V. L. (2022) · Cells · doi:10.3390/cells11233818 · Cited by 21
Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types
Guo, B., Wang, Y., Liu, W., & Zhang, S. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-022-02968-8 · Cited by 17
The Prognosis of Cancer Depends on the Interplay of Autophagy, Apoptosis, and Anoikis within the Tumor Microenvironment
Gulia, S., Chandra, P., & Das, A. (2023) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-023-01179-4 · Cited by 17
Identification of a Prognostic Immune Signature for Esophageal Squamous Cell Carcinoma to Predict Survival and Inflammatory Landscapes
Zhang, C., Luo, Y., Zhang, Z., Zhang, Z., Zhang, G., Wang, F., Che, Y., Fang, L., Zhang, Y., Sun, N., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.580005 · Cited by 16
Self-citation
Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
Knight, A., Říhová, L., Králová, R., Penka, M., Adam, Z., Pour, L., Piskáček, M., & Hájek, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163717 · Cited by 15
Identification of a ceRNA Network in Lung Adenocarcinoma Based on Integration Analysis of Tumor-Associated Macrophage Signature Genes
Zhang, L., Zhang, K., Liu, S., Zhang, R., Yang, Y., Wang, Q., Zhao, S., Li, Y., Zhang, Y., & Wang, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.629941 · Cited by 15
Self-citation
Highlights of Immunomodulation in Salmonella-Based Cancer Therapy
Pangilinan, C., & Lee, C.-H. (2021) · Biomedicines · doi:10.3390/biomedicines9111566 · Cited by 12
Hereditary Diffuse Gastric Cancer: A 2022 Update
Kole, C., Charalampakis, N., Sakellariou, S., Papaxoinis, G., Apostolou, K. G., Machairas, N., Papanikolaou, I. S., & Schizas, D. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12122032 · Cited by 16
Nanocarrier-based drug delivery via cell-hitchhiking: Emphasizing pharmacokinetic perspective towards taming the “big-old” tumors
Famta, P., Shah, S., Jain, N., Srinivasarao, D. A., Vambhurkar, G. B., Shahrukh, S., Murthy, A. N., Ahmed, T., Pandey, G., Sharma, A., et al. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105050 · Cited by 14
Stromal senescence contributes to age-related increases in cancer
Ye, J., Melam, A., & Stewart, S. A. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00840-9 · Cited by 16
HydrAd: A Helper-Dependent Adenovirus Targeting Multiple Immune Pathways for Cancer Immunotherapy
Shaw, A. R., Porter, C. E., Biegert, G. W. G., Jatta, L., & Suzuki, M. (2022) · Cancers · doi:10.3390/cancers14112769 · Cited by 13
From single gene analysis to single cell profiling: a new era for precision medicine
Martino, M. T. D., Meschini, S., Scotlandi, K., Riganti, C., Smaele, E. D., Zazzeroni, F., Donadelli, M., Leonetti, C., & Caraglia, M. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01549-3 · Cited by 13
Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors
Rafia, C., Harly, C., & Scotet, E. (2020) · Immunological Reviews · doi:10.1111/imr.12920 · Cited by 14
Efferocytosis in Health and Disease
Li, C., Yang, Y., Zhou, F., Jiang, Q., Jiang, Y., Huang, X., Zhang, Y., Ye, Z., Xu, G. X., Kao, G., et al. (2025) · MedComm · doi:10.1002/mco2.70546 · Cited by 15
Self-citation
A glioneuronal tumor with CLIP2-MET fusion
Chowdhury, T., Lee, Y., Kim, S., Yu, H. J., Ji, S. Y., Bae, J. M., Won, J., Shin, J. H., Weinberger, D. R., Choi, S. H., et al. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-0131-6 · Cited by 12
The combination of novel immune checkpoints HHLA2 and ICOSLG: A new system to predict survival and immune features in esophageal squamous cell carcinoma
Zhang, C., Wang, F., Sun, N., Zhang, Z., Zhang, G., Zhang, Z., Luo, Y., Che, Y., Cheng, H., Li, J., et al. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.08.003 · Cited by 12
CXCL10-coronated thermosensitive “stealth” liposomes for sequential chemoimmunotherapy in melanoma
Xin, X., Zhou, Y., Li, J., Zhang, K., Qin, C., & Yin, L. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102634 · Cited by 12
Identification and characterization of prognosis-related genes in the tumor microenvironment of esophageal squamous cell carcinoma
Qu, J., Zhao, Q., Yang, L., Ping, Y., Zhang, K., Lei, Q., Liu, F., & Zhang, Y. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107616 · Cited by 12
Self-citation
RETRACTED ARTICLE: Tumour microenvironment programming by an RNA–RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma
Wu, L.-L., Zhao, Z., Shin, Y., Yin, Y.-Y., Raju, A., Vaiyapuri, T., Idzham, K., Son, M., Lee, Y., Sa, J., et al. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01428-5 · Cited by 9
Retracted
Epigenetic modulation of immune cells: Mechanisms and implications
Fiordoro, S., Rosano, C., Pechkova, E., Barocci, S., & Izzotti, A. (2024) · Advances in Biological Regulation · doi:10.1016/j.jbior.2024.101043 · Cited by 11
Emerging Immunotherapy Targets in Early Drug Development
Araujo, D. M., Catani, G., Mirallas, O., Pretelli, G., Sánchez-Pérez, V., Vieito, M., Braña, I., Pujol‐Borrell, R., Garralda, E., & Hernando‐Calvo, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115394 · Cited by 12
Exploring therapeutic targets and drug candidates for obesity: a combined network pharmacology, bioinformatics approach
Aloufi, B. H., Alshabrmi, F. M., Sreeharsha, N., & Rehman, A. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2265491 · Cited by 11
Targeting oncogenic signal pathway to improve cancer immunotherapy: Insights and perspectives
Yang, Q., Sun, H., & Sun, Z. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117043 · Cited by 11

Authors: Yang, L., Li, A., Lei, Q., & Zhang, Y.
Affiliations: First Affiliated Hospital of Zhengzhou University (CN)
Zhengzhou University (CN)
Corresponding author: Zhang, Yi
ORCID: Yang, Li
Li, Aitian
Zhang, Yi
Venue: Journal of Hematology & Oncology
Publisher: Springer Science and Business Media LLC
Published: 2019-11-27
Volume: 12
Issue: 1
Pages: 125-125
ISSN: 1756-8722 (ISSN-L)
DOI: 10.1186/s13045-019-0804-8
PMC: PMC6880373
OpenAlex: W2990431514
Cited by: 215
References: 126
Citations by year: 2026: 27 · 2025: 40 · 2024: 29 · 2023: 31 · 2022: 39 · 2021: 28 · 2020: 20
FWCI: 2.07
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Journal of Hematology & Oncology (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Natural Science Foundation of China (U1804281, 81771781, 81602024)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords: immunosuppressive tumor microenvironment, tumor immune evasion, cancer immunotherapy resistance, immune exclusion, interpatient heterogeneity, somatic mutations, immune cell infiltration, therapeutic target
MeSH terms: Antineoplastic Agents, Humans, Immunosuppressive Agents, Immunotherapy, Neoplasms, Signal Transduction, Tumor Escape, Molecular Targeted Therapy, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks